
An Avastin intravitreal (intraocular) injection is the administration of medication directly into the eye, at the site where the highest concentration and the strongest...
Price from 225 €Price on 10.09.2026.: 225 €An Avastin intravitreal (intraocular) injection is the administration of the medication directly into the eye, at the site where the highest concentration and the strongest effectiveness of the medication are achieved.
We use them to treat many eye diseases, most often for the treatment of
The procedure is practically painless, because a very thin and small needle is used and the eye is first anaesthetised with anaesthetic drops.
The procedure is performed in an operating theatre for complete sterility.
Before the procedure anaesthesia is given to the eye in the form of eye drops
The procedure is short and is a simple injection into the eye that the patient does not feel.
After the procedure For the first few days, depending on the type of medication used, the patient may see floaters “drifting” in front of the eye after the procedure. This is the medication in the vitreous of the eye, which soon settles to the bottom of the eyeball and causes no further difficulty. Over a period of time, usually 1-3 months (depending on the type of medication), the medication gradually dissolves.
The latest medicines for treating the wet form of age-related macular degeneration, which prevent the growth of new blood vessels in the eye (anti-VEGF), and corticosteroids (triamcinolone acetonide and the like), which act on oedema and inflammatory changes in the retina, are administered by intravitreal injection.
Avastin® (bevacizumab) which non-selectively blocks the endothelial growth factors of blood vessels in the eye (VEGF). It is a medicine used primarily in the treatment of colon cancer, where, likewise, by blocking the growth of new blood vessels it also stops tumour growth. In recent years Avastin has been widely used worldwide to treat the wet form of macular degeneration, and new indications such as diabetic retinopathy are emerging. Its use in the eye is so-called “off-label use” (use outside the recommended indication), and before the procedure the patient must be fully informed of the risks of such use and sign written consent for the procedure.
(pegaptanib) is also a medicine from the anti-VEGF group, which selectively blocks the endothelial growth factors of blood vessels in the eye. Its primary indication is the wet form of age-related macular degeneration, and it is approved by the US FDA for that indication. Its selective action provides far greater safety of use in patients with an increased risk of cardiovascular disease.
(ranibizumab) is also a non-selective anti-VEGF medicine approved by the FDA for the treatment of the wet form of macular degeneration (ARMD).
Kenalog® (triamcinolone acetonide) is a corticosteroid that we administer intravitreally in order to reduce macular oedema in diabetic retinopathy, vascular occlusions, in the wet form of age-related macular degeneration in combination with anti-VEGF medicines or PDT therapy, in some inflammatory eye diseases and other rarer conditions.
Točan iznos ovisi o nalazu i procjeni liječnika. Sve cijene pogledajte u cjeniku.
Full price listCijena prema važećem cjeniku poliklinike.

Specialist in ophthalmology, founder of Poliklinika Knezović
Expert in diseases of the anterior segment of the eye and in laser treatment of keratoconus. More than 25 years in ophthalmology, with training at leading centres around the world.
Every eye is different. The doctor decides on the method only after an examination and diagnostics. Book an appointment and you will receive a clear recommendation and an exact quote, with no obligation.